Testing the external validity of the POUT III trial (adjuvant platnium-based chemotherapy in upper tract urothelial carcinoma) in a North American cohort

CONCLUSIONS: While the primary disease stage was similar, the rate of advanced nodal disease was significantly higher in NCDB, which might be explained partially by the more extensive lymph node dissection performed in the latter. These differences warrant caution when applying the POUT III findings to North American patients.PMID:38522975 | DOI:10.1016/j.urolonc.2024.01.035

Source: Urologic Oncology - March 24, 2024 Category: Urology & Nephrology Authors: Nicholas James Corsi Alex Stephens Marco Finati Taylor Malchow Chase Morrison Matthew Davis Keinnan Hares Matthew P Corsi Sohrab Arora Giuseppe Chiarelli Giuseppe Ottone Cirulli Riccardo Autorino Akshay Sood Craig Rogers Firas Abdollah Source Type: research